Podcasts about myelofibrosis

In this Editor's Special episode of The HemOnc Pulse, MD Anderson Cancer Center's Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. How does someone keep a good mood after receiving one devastating medical diagnosis after another? Retired California Juvenile Hall Officer Tyrone “Ty” Armstrong Sr. has faced a disabling injury, congestive heart failure, cancer, nightmares, and anxiety, but he refuses to let illness define his life. The Law Enforcement Talk Radio Show and Podcast social media like their Facebook , Instagram , LinkedIn , Medium and other social media platforms. For Tyrone “Ty” Armstrong Sr., the answer is found in purpose, creativity, faith in the future, and a determination to keep contributing, even when his body makes every day more difficult. The Podcast is available for free on the Law Enforcement Talk Radio Show and Podcast website, also on Apple Podcasts, Spotify, YouTube, iHeartradio and most major podcast platforms. #LawEnforcementTalk #Free #Podcast #Radio Armstrong is a retired Juvenile Hall Officer from California who was forced to leave his career because of a serious foot injury. Retirement, however, was only the beginning of a series of life-altering health battles. Supporting articles about this and much more from Law Enforcement Talk Radio Show and Podcast in platforms like Medium , Blogspot and Linkedin. He was hospitalized with congestive heart failure. His heart function reportedly dropped to approximately 15 percent. Then doctors discovered myelofibrosis, a rare form of bone marrow cancer. The illnesses changed his physical abilities, interrupted his career, and contributed to nightmares and anxiety. Yet Armstrong continues to search for reasons to smile, create, and connect with other people. His remarkable story is featured on the Law Enforcement Talk Radio Show and Podcast, available on Apple Podcasts, Spotify, YouTube, and other major podcast platforms. Additional content from the interview is shared on Facebook and Instagram. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. He shares the full story as a guest on the Law Enforcement Talk Radio Show and Podcast, available on Apple, Spotify, YouTube, and other major podcast platforms. The interview is also featured across Facebook and Instagram. The conversation explores the challenges of working inside a Juvenile Hall facility, the health crisis that transformed Armstrong's life, and how he keeps a good mood in spite of severe health problems. The Difficult Work of a Juvenile Hall Officer Most people understand that police officers, corrections officers, and firefighters work in dangerous environments. The challenges faced by Juvenile Hall Officers, however, frequently receive far less public attention. Juvenile detention facilities house young people who may be accused or convicted of serious crimes. Some have histories involving violence, gangs, drugs, unstable homes, neglect, or abuse. Others struggle with mental health conditions, anger, fear, and distrust of authority. Juvenile officers must maintain security while working with young people whose lives may already be moving in a dangerous direction. The job requires vigilance, patience, communication skills, emotional control, and the ability to respond quickly when a situation turns violent. Officers may have to break up fights, enforce rules, identify manipulation, prevent escapes, and protect detainees from one another. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. The episode is available across major platforms including their website, Apple Podcasts, Spotify, YouTube, with highlights shared across their Facebook, Instagram, and LinkedIn profiles. At the same time, the work is not exclusively about discipline. A Juvenile Hall Officer may also become one of the few stable adults in a young person's life. A firm but respectful conversation can sometimes influence a teenager long after that person leaves custody. Armstrong experienced those competing responsibilities firsthand during his career in California. He understood the importance of safety and authority, but he also recognized that the young people inside the facility were not necessarily beyond hope. His work demanded physical stamina and emotional resilience. When a foot injury forced him into retirement, he lost more than employment. He also lost the routine, responsibilities, professional identity, and sense of purpose connected to his career. The transition would have been difficult under any circumstances. The severe medical problems that followed made it even more challenging. Hospitalized With Congestive Heart Failure Armstrong's life changed dramatically when he developed congestive heart failure and required hospitalization. Congestive heart failure, commonly abbreviated as CHF, is a chronic condition in which the heart cannot pump blood as efficiently as the body needs. When the heart's pumping ability weakens, blood and fluid can back up in the lungs and other tissues. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. Heart failure can have several underlying causes, including coronary artery disease, previous heart attacks, high blood pressure, heart valve disease, cardiomyopathy, diabetes, and obesity. Treatment may include medication, dietary changes, carefully monitored physical activity, implanted medical devices, and frequent evaluation by medical professionals. The treatment plan depends on the individual patient's condition and the cause and severity of the heart failure. For Armstrong, the diagnosis was especially frightening because his heart was reportedly functioning at approximately 15 percent. A number that low can transform even routine activities into exhausting challenges. Walking, climbing stairs, getting dressed, or completing household tasks may require far more effort than before. The person must also live with the knowledge that the heart, an organ that never gets to take a break, is severely weakened. Many people would understandably respond with despair. Not Armstrong. That decision did not erase the seriousness of his illness. It did not mean he ignored fear, anxiety, or physical limitations. Instead, he began searching for a new way to create meaning within the boundaries imposed by his health. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. The Podcast is available for free on the Law Enforcement Talk Radio Show and Podcast website, also on Apple Podcasts, Spotify, YouTube, iHeartradio and most major podcast platforms. Another Devastating Diagnosis: Myelofibrosis After experiencing congestive heart failure, Armstrong received another life-changing diagnosis: myelofibrosis. Myelofibrosis is a rare form of bone marrow cancer. It disrupts the body's normal production of blood cells and can cause extensive scarring within the bone marrow. The disease may lead to severe fatigue, weakness, anemia, an enlarged spleen, bone pain, abnormal bleeding, and a greater vulnerability to infections. The experience can share certain symptoms or blood-related complications with other serious disorders, although it is a distinct medical condition. For Armstrong, the cancer diagnosis arrived on top of an already dangerous heart condition. He was no longer dealing with one isolated medical problem. He was living with multiple severe health conditions that could affect his strength, energy, mobility, independence, and future. The emotional consequences were significant. Armstrong began experiencing nightmares and anxiety. These symptoms became part of his life alongside the physical illnesses. Serious medical diagnoses can create a persistent sense of uncertainty. A patient may worry about the next test, the next appointment, the next treatment, or an unexpected change in symptoms. Even on relatively good days, the fear of what might happen next can remain in the background. Armstrong acknowledges those struggles. His positive outlook is not based on pretending everything is fine. His story is powerful because his optimism exists alongside pain, fear, and uncertainty. How He Keeps a Good Mood in Spite of Severe Health Problems Armstrong cannot control every aspect of his medical condition, but he can decide where to direct his attention and energy. He keeps moving forward by concentrating on creativity, service, and the possibility of building something valuable for other people. Rather than viewing retirement and illness as the end of his productive life, Armstrong embraced web development. At 64 years old, he began using technology to create a new mission. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. The Law Enforcement Talk Radio Show and Podcast continues bringing listeners real conversations from the front lines of crime, policing, trauma, survival, and healing. He designed an innovative video vlog intended to provide an all-in-one visual browsing experience. His goal was to create a platform with entertainment, information, and resources for people who prefer learning and engaging through video. For Armstrong, it is evidence that purpose can continue after retirement, disability, and devastating medical diagnoses. It gives him a reason to create, plan, learn, and imagine what the future could become. When serious illness removes a person's former career or physical abilities, developing a new source of purpose can help restore direction. The new mission does not have to resemble the old one. It simply needs to provide a meaningful reason to continue engaging with life. Building Something for Visual Learners Armstrong's vision extends beyond entertainment. He wants his video vlog to become a global resource for visual learners, people who understand and retain information more effectively when it is presented through images, demonstrations, and video. Video can make information more approachable for users who struggle with long written explanations. It can show a process in action, combine audio with visual examples, and give people the ability to pause, replay, and learn at their own pace. Armstrong dreams of collaborating with video creators and content enthusiasts around the world. He wants to expand the platform, reach international audiences, and develop an online community where video education and visual stimulation are easily accessible. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. Supporting articles about this and much more from Law Enforcement Talk Radio Show and Podcast in platforms like Medium , Blogspot and Linkedin. The diagnosis of myelofibrosis did not destroy that dream. In some ways, it made the mission feel more urgent. Armstrong understands that his health is fragile. Rather than allowing that reality to paralyze him, he uses it as motivation to keep building. His attitude carries an important message: A person does not need perfect health or ideal circumstances to make a difference. Positivity Does Not Mean Denying Reality Stories about resilience can sometimes create the false impression that people should remain cheerful at all times. That is not realistic, especially for someone living with heart failure, cancer, chronic physical limitations, nightmares, and anxiety. Keeping a good mood does not mean Armstrong never has difficult days. It does not mean he is free from fear or frustration. It does not mean that a positive attitude can replace medical treatment. Instead, his outlook appears to be rooted in refusing to surrender his entire identity to illness. He is not only a patient. He is a retired Juvenile Hall Officer, father, web developer, creator, visual thinker, and man with an ambitious idea. His illnesses are part of his story, but they are not the whole story. That distinction can be essential for people facing long-term health problems. Medical appointments naturally focus on symptoms, test results, medications, and treatment plans. While those issues are necessary, patients also need reasons to see themselves as complete human beings with interests, relationships, abilities, and dreams. Armstrong's creative work gives him something to discuss besides illness. It allows him to measure progress through ideas developed and connections made, not only through medical numbers. Nightmares, Anxiety, and the Emotional Toll of Illness Armstrong's physical conditions are only part of the battle. He also lives with nightmares and anxiety that developed during his medical journey. A severe health emergency can leave a lasting psychological impact. Hospitalization, frightening symptoms, loss of independence, and uncertainty about survival may continue to affect a person long after the immediate crisis has passed. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. The show is distributed through Apple Podcasts, Spotify, YouTube, iHeartradio and other podcast platforms. Its interviews are also promoted across Facebook, Instagram, and other social media channels. Nightmares can interrupt restorative sleep. Anxiety can make ordinary sensations feel threatening. A rapid heartbeat, shortness of breath, or sudden fatigue may create immediate fear for someone with a serious cardiac condition. Poor sleep and constant worry can also make physical symptoms more difficult to manage. Armstrong's willingness to discuss these struggles is important because many retired officers and first responders hesitate to talk openly about emotional health. Careers built around strength, control, and responsibility can make it difficult to admit fear or ask for help. Lessons From His Career That Still Serve Him Although Armstrong is no longer working inside a Juvenile Hall facility, some of the skills developed during his career remain useful. Juvenile officers learn to remain alert, manage unpredictable situations, communicate with difficult personalities, and maintain control under pressure. They must adapt quickly because the environment can change without warning. Those abilities can also help someone facing severe illness. Medical conditions are unpredictable. Treatment plans change. Energy levels rise and fall. Some days allow for productivity, while other days require rest. Armstrong has learned to work within those changing limits. He cannot always control what happens to his health, but he can control whether he continues searching for meaningful ways to use his time and experience. A Life With Purpose After Retirement Retirement caused by injury can feel very different from a planned retirement. A person may not have time to prepare financially or emotionally. The career can end before the individual is ready to leave, creating a painful loss of identity and direction. Armstrong's transition was followed by congestive heart failure and cancer, making the process even more disruptive. Still, he found a new path through web development. His story illustrates that purpose is not limited to a job title. A career may end, but a person's ability to contribute does not necessarily end with it. Purpose can be rebuilt through creativity, entrepreneurship, mentoring, volunteering, family, advocacy, or community involvement. For Armstrong, it emerged through technology and video. His goal is not simply to pass the time. He wants to create something capable of reaching people around the world. How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. The episode is available across major platforms including their website, Apple Podcasts, Spotify, YouTube, with highlights shared across their Facebook, Instagram, and LinkedIn profiles. That is how he keeps looking ahead. Hear Tyrone Armstrong's Full Story Tyrone “Ty” Armstrong Sr. has experienced a disabling foot injury, medical retirement, congestive heart failure, severely reduced heart function, myelofibrosis, nightmares, and anxiety. Yet he continues to build, dream, and search for ways to help others. His experience offers a powerful answer to the question of how he keeps a good mood in spite of severe health challenges. He does not deny the seriousness of his condition. He chooses not to let the condition take ownership of everything he is. The full interview with the retired California Juvenile Hall Officer is featured on the Law Enforcement Talk Radio Show and Podcast. Listeners can hear his story on Apple Podcasts, Spotify, YouTube, and other major podcast platforms. Additional interview content and updates are available through Facebook and Instagram. Armstrong's journey is not a simple story about “staying positive.” It is a story about rebuilding purpose after a career-ending injury and continuing to create while living with potentially life-threatening illnesses. His health has changed what he can do. It has not taken away his determination to do something meaningful. For anyone struggling with retirement, disability, cancer, heart disease, anxiety, or an uncertain future, his example carries an important message: Life may change without permission, but purpose can still be created, one idea, one connection, and one day at a time. Listen to the Law Enforcement Talk Radio Show and Podcast on their website, Facebook, Instagram, YouTube, Apple Podcasts, Spotify, iHeartRadio, and most major podcast platforms. Get the Free Clubhouse App, it is Drop In Social Audio. Think of it as your own talk radio show on your phone, and best of all it is free. Be sure to look for me and follow me, that's John J Wiley or @letradioshow you can do all that here. The Law Enforcement Talk Radio Show and Podcast social media like their Facebook , Instagram , LinkedIn , Medium and other social media platforms. You can contact John J. “Jay” Wiley by email at Jay@letradio.com , or learn more about him on their website . Find a wide variety of great podcasts online at The Podcast Zone Facebook Page , look for the one with the bright green logo. Be sure to check out our website . Be sure to follow us on X , Instagram , Facebook, Pinterest, Linkedin and other social media platforms for the latest episodes and news. Listeners can find the show across Apple, Spotify, YouTube, Facebook, Instagram, and other podcast and social media platforms. Learn and get access to money saving tips and how to increase your net worth at www.LetSavings.com For a community of like minded individuals from all over the planet that want to improve their lives, relationships and business. Learn what they need, and develop the life that they've always wanted. We host weekly rooms on the Clubhouse Drop In Social Audio App. The App and Your Confident Life rooms are free of charge. You can get more information about Clubhouse and Your Confident Life for free here. Download the Free Ebook about ways and tips to improve your health. You can get the ebook for free at www.LetHealthy.com How He Keeps a Good Mood in Spite of Severe Health Challenges: A Retired Juvenile Officer's Inspiring Story. Attributions SloppBoxx Video Entertainment Vlog Google Wikipedia Facebook Facebook Group Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlights from the PER® CME activity "Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Ruben Mesa, MD, FACP; Andrew Kuykendall, MD; and Sangeetha Venugopal, MD, MS; discuss evolving management strategies for patients with MF, and considerations for selecting therapy based on patient-related and disease-related factors.Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/cases-and-conversations-applying-the-evidence-real-world-strategies-to-optimize-care-for-patients-with-myelofibrosis-jadnThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Bristol Myers Squibb and PharmaEssentia.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space. Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies: OPTI-AML: explored the findings on the use of venetoclax in combination with azacitidine for newly diagnosed AML patients, comparing 14-day versus 28-day treatment regimens and their impact on cytopenias and overall outcomes. KOMET-007: promising early data on menin inhibitors, specifically Ziftomenib, in frontline settings for patients with NPM1 and KMT2A rearrangements, and how it may change the landscape of AML treatment. SENTRY: analyzed the combination of ruxolitinib and selinexor for myelofibrosis, discussing its effects on spleen volume reduction and overall survival, as well as the implications of side effects. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/  Tune in for an insightful discussion on the future of leukemia treatment and the importance of genetic markers in therapy decisions. Don't forget to like, subscribe, and check out our other conference highlights from ASCO and EHA! #EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/YTA865. NCPD/ILNA credit will be available until June 13, 2027.United for Better Myelofibrosis Care: Nurse–Patient Teamwork for Personalized Delivery of JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

In today's episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the pharmaceutical and biotech sectors, where significant scientific advancements, regulatory shifts, and strategic business maneuvers are reshaping patient care and therapeutic approaches. A pivotal moment recently unfolded with Ipsen's acquisition of Kartos Therapeutics for up to $1.75 billion. This strategic move adds navtemadlin, a promising myelofibrosis candidate, to Ipsen's oncology pipeline. Navtemadlin is a small molecule inhibitor targeting MDM2, a crucial regulator of the tumor suppressor p53. This acquisition reflects a strategic emphasis on expanding therapeutic options in hematologic oncology, aiming to improve outcomes for patients with myelofibrosis—a rare and debilitating bone marrow disorder. In regulatory advancements, Viridian Therapeutics achieved a significant milestone with FDA approval of Lumvoa (veligrotug-vvze) for treating thyroid eye disease across both active and chronic stages. This monoclonal antibody targets IGF-1R, addressing an unmet need in autoimmune conditions by potentially altering disease progression and improving patient quality of life. Concurrently, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) secured EU approval for HER2-positive metastatic solid tumors after successful Phase 2 trials. Enhertu's role as an antibody-drug conjugate highlights a breakthrough in targeting cancer cells more precisely while sparing healthy tissues, underscoring the growing importance of personalized medicine in oncology. The clinical trial landscape saw pivotal results with AstraZeneca's efzimfotase alfa demonstrating efficacy in Phase 3 trials for hypophosphatasia—a rare bone disease characterized by defective bone mineralization due to enzyme deficiencies. This protein therapy aims to replace deficient alkaline phosphatase enzymes, offering hope for improved skeletal outcomes in affected children. Furthermore, BridgeBio Pharma's infigratinib showed promise in Phase 3 trials for treating achondroplasia by demonstrating significant growth improvements. As a fibroblast growth factor receptor (FGFR) inhibitor, it underscores the potential of targeted therapies in addressing genetic disorders. On the business development front, Zymeworks' acquisition of Theravance for $929 million adds the COPD drug Yupelri to its portfolio alongside lucrative royalty arrangements. Yupelri is a long-acting muscarinic antagonist (LAMA) that offers once-daily bronchodilation for COPD patients. This strategic move bolsters Zymeworks' respiratory franchise and highlights the ongoing consolidation trend in the industry as companies seek growth through diversification and enhanced therapeutic offerings. In parallel, Talawar Therapeutics is planning a $285 million SPAC merger to advance its bispecific antibody for eczema treatment. Similarly, Lycia Therapeutics raised $75 million in Series D funding to progress its extracellular protein degrader pipeline aimed at autoimmune diseases. These investments signal robust interest in novel modalities such as bispecific antibodies and targeted protein degradation technologies that promise new therapeutic avenues. However, not all news was positive. The FDA rejected Sobi's NASP (pegadricase) application due to manufacturing issues, highlighting ongoing challenges firms face in meeting regulatory standards for complex biologics. Additionally, Evommune's Evo756 failed its primary endpoint in Phase 2b trials for chronic spontaneous urticaria, illustrating the high-risk nature of drug development. Looking at the broader industry trends, Roche's launch of Axelios 1 represents a strategic push into the gene sequencing arena, directly challenging Illumina's market dominance. As precision medicine continues to gain traction, advancements in gene sequencing technologies are likely to play an instrumental role in personalized medicine strategies, offering more tailored treatment options based on genetic profiles. Finally, we see significant shifts driven by recent regulatory changes and scientific breakthroughs across the sector. The FDA's revised stance on rare disease drug approval criteria could expedite processes for companies like Skyhawk Therapeutics and Biohaven, providing new opportunities to bring treatments to market more swiftly. These regulatory adjustments reflect an evolving landscape where innovation is poised to meet unmet medical needs more efficiently. In conclusion, these developments underscore a dynamic pharmaceutical and biotech landscape characterized by strategic acquisitions, regulatory successes, and scientific advancements aimed at addressing complex diseases with innovative therapies. As these sectors continue to evolve, stakeholders must navigate a complex interplay of technological advancements, regulatory scrutiny, and competitive pressures to drive meaningful advancements in healthcare outcomes. Stay tuned with Pharma Daily as we continue to explore these significant shifts shaping the future of healthcare and drug development. Thank you for joining us today as we unpack these pivotal stories impacting our industry.Support the show

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications

Tania Jain, MBBS What does a myelofibrosis (MF) diagnosis really mean, and how does it fit within a group of conditions called myeloproliferative neoplasms, or MPNs? In this episode, we're joined by Dr. Tania Jain of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, who helps break it all down in a clear and approachable way. She discusses how myelofibrosis affects the bone marrow, common symptoms to watch for, and how treatment options are tailored to each person. From managing day-to-day challenges to understanding when more advanced treatments may be considered, this conversation focuses on what matters most to patients and families. As Dr. Jain shares, “every patient writes their own story,” noting that advancing research offers genuine hope. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Myelofibrosis (MF) DIPSS/DIPSS plus myelofibrosis scoring Myelofibrosis: Charting the Course for Care Allogeneic stem cell transplantation Acute myeloid leukemia (AML) Clinical Trial Support Center Online Chat Additional Blood Cancer United Support Resources: Information Specialists Financial support Free Nutrition Consultations Free telephone/web patient programs Free booklets Patient Community Support groups Caregiver support Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by Takeda Oncology.The post Myelofibrosis (MF): More Options, More Hope first appeared on The Bloodline with Blood Cancer United Podcast.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027.Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027.Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care. Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the Indian pharmaceutical giant into international markets. This deal not only amplifies Sun Pharma's footprint but also integrates Organon's strong focus on women's health and biosimilars into its portfolio. It's a strategic move that underscores the increasing trend of cross-border mergers as companies seek to diversify and enhance their global presence. As the largest-ever overseas acquisition by an Indian firm, this transaction is emblematic of the growing importance of global consolidation in the pharma industry. Meanwhile, Astellas Pharma faces a mixed fiscal outlook with its prostate cancer drug Xtandi. While Xtandi experienced a modest sales increase in 2025, a projected decline for 2026 has prompted Astellas to pivot towards developing new medicines. This highlights the critical dependence on innovation within the industry to sustain growth, especially as competition intensifies. In the realm of ATTR amyloidosis treatments, Pfizer has reached a settlement with two generic manufacturers over its drug Vyndamax. This resolution is crucial in stabilizing the market amidst rising generic competition, which can significantly influence pricing and market dynamics. Such settlements are an integral part of maintaining competitive positioning in crowded therapeutic spaces. Ligand Pharmaceuticals' strategic purchase of XOMA for $739 million signals a broader trend of consolidation among biotech royalty aggregators. This acquisition aligns with Ligand's strategy to augment its portfolio through mergers and acquisitions—a recurring theme as biotech companies strive to streamline operations and expand their competitive edge. The competition within the oral GLP-1 market is intensifying, particularly with Eli Lilly's delayed launch of Foundayo inadvertently benefiting Novo Nordisk's market position. This rivalry underscores the fierce race to dominate the lucrative obesity management sector, highlighting how pivotal timing can be in gaining market share. The FDA's recent allocation of national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics marks a significant regulatory shift towards embracing psychedelic therapies. These vouchers could expedite development timelines, thereby accelerating patient access to novel treatments that have traditionally been underexplored. Thermo Fisher Scientific's robust start to 2026 showcases how strategic acquisitions like that of Clario can drive growth. This reflects broader industry trends where biopharma companies leverage technological advancements to enhance capabilities in clinical trial support and data management. In gene editing news, Intellia Therapeutics is advancing towards FDA approval for its in vivo CRISPR therapy following successful Phase 3 trials. This progress heralds a new era for gene editing technologies in treating genetic disorders, underscoring their potential to revolutionize therapeutic approaches. Eli Lilly continues its aggressive acquisition strategy by purchasing Ajax Therapeutics for $2.3 billion. This acquisition focuses on next-generation JAK inhibitors for myelofibrosis, aligning with Lilly's broader goal to diversify its pipeline and maintain its leadership in innovative therapeutics. Recent studies have also shed light on how an endoscopic procedure used in Europe can aid patients on Eli Lilly's tirzepatide in maintaining weight loss post-treatment. This finding could significantly impact long-term obesity management strategies, offering new insights into sustainaSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027.Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/KCA865. CME/CPE/IPCE credit will be available until April 30, 2027.Dispensing High-Quality Care for Myelofibrosis: Pharmacist Leadership in Delivering Effective JAKi Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.The pharmaceutical and biotech sectors are navigating a period of profound transformation, marked by significant scientific developments, regulatory challenges, and strategic realignments. In 2025, several major pharmaceutical companies collectively reduced their workforce by over 22,000 employees. This was a strategic response to the looming $300 billion patent cliff, which is expected to significantly impact the sector as numerous high-revenue-generating drugs lose patent protection. Such workforce reductions highlight the industry's need to innovate rapidly to offset potential revenue losses.In a pivotal legal development, a massive class action lawsuit seeking RICO penalties against Takeda and Eli Lilly has been allowed to proceed by the Supreme Court. This decision underscores the increasing legal scrutiny pharmaceutical companies face over their business practices. Should the prosecution succeed, substantial financial penalties could be imposed on these companies, potentially reshaping corporate governance and compliance frameworks across the industry.In terms of drug development and acquisitions, Gilead Sciences' $2.2 billion acquisition of Ouro marks a strategic pivot towards autoimmune therapeutics. This acquisition enriches Gilead's portfolio with a promising autoimmune T-cell engager and revitalizes its partnership with Galapagos, a Belgian biotech firm. Such deals are crucial as companies seek to bolster their pipelines with innovative therapies addressing unmet medical needs.Karyopharm's recent mixed results from its Phase 3 trial of Expovio in combination with Jakafi for treating myelofibrosis illustrate the complexities and challenges inherent in oncology drug development. The company plans to engage with the FDA to discuss these outcomes, indicating a cautious yet hopeful approach toward potential approval. This scenario underscores the high-stakes environment of clinical trials where mixed results can significantly influence regulatory decisions and market strategies.Meanwhile, Eli Lilly's decision to withdraw certain insulin products from European markets by 2027 reflects shifts in strategic priorities amidst regulatory pressures and market dynamics in Europe. This move may indicate a broader trend of pharmaceutical companies reassessing product portfolios in response to evolving healthcare policies and market demands.The year also saw WuXi Biologics expanding its project portfolio significantly with U.S. clients, despite geopolitical uncertainties. This trend highlights the increasing globalization of drug development and manufacturing processes, driven by a growing demand for contract research, development, and manufacturing services.On the technology front, artificial intelligence continues to reshape various facets of the life sciences industry. AI-driven platforms are not only optimizing engagement strategies but also enhancing operational efficiencies within life sciences teams. These tools offer flexibility that allows organizations to adapt workflows according to specific needs rather than being confined by rigid systems.However, challenges remain as evidenced by Aardvark's decision to halt trials for its obesity candidate due to cardiac concerns. This pause reflects ongoing safety challenges in drug development that necessitate robust risk management strategies.In financial developments, Wilmington PharmaTech's commitment of $50 million towards expanding its API production capacity in Delaware signals confidence in future demand for complex custom APIs. However, NIH grant cuts disproportionately affecting women and early-career scientists raise concerns about diversity and sustainability within the scientific workforce.The strategic investments continue as Novartis announces a substantial commitmeSupport the show

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠Myelofibrosis ⁠from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

In this episode of Hema Now, we take a deep dive into myeloproliferative neoplasms (MPN), with a particular focus on myelofibrosis, one of the most complex and challenging MPNs to manage. Ciro Rinaldi discusses what distinguishes myelofibrosis from other chronic MPNs, the biological drivers of disease progression, and the critical role of inflammation and the bone marrow microenvironment. The conversation also explores emerging combination therapies, translational research hurdles, and how the management of myelofibrosis may evolve over the next decade. Timestamps:   00:00 – Introduction  00:59 – Myeloproliferative neoplasms  04:00 – Myelofibrosis  09:58 – Ciro's interest in the field  13:39 – Disease drivers & progression to aggressive states  17:40 – Inflammation and the bone marrow environment  22:19 – Novel targets  27:45 – Splenomegaly and MPNs  32:19 – Translational research  36:25 – Future of myelofibrosis management  38:51 – Ciro's three magic wishes  

Send us a textIn this episode, we discuss an approach to myelofibrosis, including a review of new treatment agents that just received approval in Canada in 2025! Written by: Dr. Ayesha Warsi. Reviewed by: Drs. Zachary Leiderman, Clarissa Skorupski, and Ryan Luther.Support the show

Please visit answersincme.com/860/99519635-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Guillermo Garcia-Manero, MD and John Mascarenhas, MD. In this activity, experts in Myelodysplastic Syndromes discuss the latest data for the treatment of anemia in patients with MDS and myelofibrosis. Upon completion of this activity, participants should be better able to: Discuss the latest data for the treatment of anemia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF); and Translate the latest data into real-world treatment plans for the treatment of anemia.

Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics:  Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46) Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09) Discussion: Asymptomatic MF; re-reads of pathology reports; "triple-negative" MF; secondary causes — Laura C Michaelis, MD (22:47) Discussion: Ruxolitinib-associated dermatologic cancers and weight gain — Prithviraj Bose, MD (27:34) Managing MF in Patients with Anemia — Dr Oh (30:21) Case: A man in his early 70s with splenomegaly and mild fatigue is diagnosed with JAK2 V617F-mutant primary MF and receives momelotinib — Dr Michaelis (42:34) Discussion: Post-hoc analysis from the SIMPLIFY-1 trial — Dr Bose (46:20) Managing MF in Patients with Thrombocytopenia — Dr Rampal (49:57) Discussion: MF with moderate thrombocytopenia — Dr Michaelis Case: A man in his mid 60s with primary MF and anemia, thrombocytopenia and splenomegaly has a low JAK2 V617F allele frequency — Dr Mascarenhas (1:05:46) Promising Novel Agents Under Investigation for MF — Prof Harrison (1:11:21) Case: A woman in her late 70s with primary MF with CALR1 and SF3B1 mutations and anemia receives luspatercept — Dr Michaelis Discussion: Luspatercept for MF-associated anemia — Dr Bose (1:24:52) Discussion: Promising novel therapies — Dr Mascarenhas (1:28:24) Current and Future Management of Systemic Mastocytosis — Dr Kuykendall (1:32:40) Discussion: Initial assessment of patients diagnosed with systemic mastocytosis; avapritinib dosing — Dr Bose (1:49:12) Discussion: Systemic mastocytosis with associated hematologic neoplasm — Dr Bose (1:52:24) Discussion: Bezuclastinib for systemic mastocytosis — Dr Bose (1:55:23) CME information and select publications  

Prof Claire Harrison from Guy's and St Thomas' NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter: Rami Komrokji, MDSenior Member, Vice ChairSection Head – Leukemia and MDSDepartment of Malignant HematologyH. Lee Moffitt Cancer CenterProfessor of Oncologic SciencesUniversity of South FloridaTampa, FloridaContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target

- Overview & Updates on Myelofibrosis (MF) in the Context of Infectious Diseases - Staging & Diagnosing - Current Standard of Care - New & Emerging Treatment Approaches - Understanding Common Signs & Symptoms - Strategies to Reduce Potential Complications of MF - Clinical Trial Updates - How Research Contributes to Treatment Options - Working with the Health Care Team to Manage Symptoms, Treatment Side Effects, Discomfort & Pain - The Importance of Adherence to Treatment - Communicating with Your Health Care Team About Staging & Progression - Talking with Your Doctor About What Symptoms Should Prompt You or Your Caregiver to Call the Office - Quality-of-Life Concerns & Recommendations to Improve Your Quality-of-Life - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

In today's episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.   In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center. Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly. Key topics covered in this episode include: • The initial workup and diagnostic criteria for myelofibrosis • The role of next-generation sequencing and bone marrow biopsy • Risk stratification using the IPSS and DIPSS scoring systems • First-line treatment options, including the four available JAK inhibitors: Ruxolitinib, Momelotinib, Fedratinib, and Pacritinib • Supportive care strategies for managing anemia and thrombocytopenia • The importance of clinical trials and early referral for transplant Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates of recruitment, retention, and adherence to oral therapies, coupled with a significant reduction in the risk of this difficult complication. Finally, new research indicates that hallmarks of terminal T-cell exhaustion are absent in multiple myeloma, from diagnosis through maintenance therapy. We explore these provocative and counterintuitive findings arising from profiling of blood and marrow samples.Featured Articles:Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisA controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafilHallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

In this episode, we speak with Mary Wells, who was diagnosed with primary myelofibrosis in 2018, a rare blood cancer… The post Choosing the Path Forward: Shared Decisions in Myelofibrosis Care first appeared on The Bloodline with LLS.

Featuring perspectives from Prof Claire Harrison and Dr John Mascarenhas, including the following topics: Introduction (0:00) New Biology of Myelofibrosis (1:55) Novel Regulatory T-Cell Infusion Therapy (14:57) Myelofibrosis 2025: JAK Inhibitors (Ruxolitinib) (20:39) BET Inhibitors: Pelabresib (42:03) Navtemadlin (53:20) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 2: Novel Investigational Strategies — John Mascarenhas, MD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Myelofibrosis | Faculty Presentation 1: Current Management of Myelofibrosis (MF) — Professor Claire Harrison CME information and select publications

Professor Claire Harrison from the Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications

Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  CME information and select publications here.

Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.

Drs. Bose and Pemmaraju discuss leukemic transformation in patients with myelofibrosis, reviewing its incidence, as well as risk factors, treatment, and prognosis.

Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications

Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.

A phase 3 study showed that combining pelabresib with ruxolitinib significantly improved spleen volume reduction and symptom relief in myelofibrosis patients compared to ruxolitinib alone, offering a promising new treatment option. Long-term use of gantenerumab may delay Alzheimer's dementia onset in individuals with inherited Alzheimer's, supporting the amyloid hypothesis and paving the way for future prevention strategies. Phase 3 trials demonstrated that povorcitinib, an oral JAK1 inhibitor, significantly improved clinical outcomes in adults with moderate to severe hidradenitis suppurativa, potentially offering a new treatment option. Research linked red meat allergy to bites from additional tick species, expanding the geographic risk area and highlighting the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.